How far can celebrities go when promoting certain pharmaceutical drugs. It turns out the FDA is not too happy with certain celebrities who pushing certain drugs on platforms like Instagram. Recently Kim Kardashian was paid to promote a product. Cenk Uygur and Ana Kasparian (The Point) hosts of The Young Turks discuss. Should Kim be more careful with endorsing drugs on social media? Let us know what you think in the comments below.

Read more here: http://www.slate.com/blogs/future_ten…

You would think an Instagram post of Kim Kardashian demurely brandishing a bottle of morning sickness pills wouldn’t qualify as one of the pregnant reality star’s more controversial images. But the FDA disagrees: Last week, the regulatory body sent a warning letter demanding that Kardashian take down the offending post immediately. Kardashian had written to her 42 million Instagram followers that her doctor “prescribed me #Diclegis, and I felt a lot better and most importantly, it’s been studied and there was no increased risk to the baby. I’m so excited and happy with my results that I’m partnering with Duchesnay USA to raise awareness about treating morning sickness.”

So what made the FDA so queasy? It seems that Kardashian, a paid promoter of the drug, had touted Diclegis’ benefits while failing to mention any of its risks. Her post, which garnered 460,000 likes, “misleadingly fails to provide material information about the consequences that may result from the use of the drug and suggests that it is safer than has been demonstrated,” according to the letter. Those consequences include drowsiness, difficulty operating heavy machinery, the potential for somnolence, falls, and accidents when taken in conjunction with other antihistamines or depressants like alcohol. Kardashian also failed to mention a significant limitation to the once-controversial drug’s use: It has not been studied in women with the most severe form of morning sickness, also known as hyperemesis gravidarum.

“Failure to correct the violations discussed above may result in FDA regulatory action, including seizure or injunction, without further notice,” the letter reads.